Lineage Cell Therapeutics (FRA:BT3) Tariff Resilience Score: 6/10 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BT3 Lineage Cell Therapeutics Inc FRA:BT3
78 GF Score
Price €1.04
GF Value €1.17
! 4 Warning Signs
View Full Analysis

What is Lineage Cell Therapeutics Tariff Resilience Score?

Lineage Cell Therapeutics FRA:BT3 78 Tariff Resilience Score is 6 as of Jul. 17, 2026. GuruFocus rates FRA:BT3 with a GF Score™ of 78/100 and a GF Value™ of €1.17. The stock has 4 warning signs investors should review. Among 1,370 Biotechnology companies, Lineage Cell Therapeutics ranks better than 75.99% on this metric.

Lineage Cell Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Lineage Cell Therapeutics has Lineage Cell Therapeutics operates in the biotech sector, which is less tariff-sensitive. However, its reliance on international research partnerships and potential import of specialized equipment could pose some risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Lineage Cell Therapeutics might have Average Resilient.

Lineage Cell Therapeutics  (FRA:BT3) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Lineage Cell Therapeutics Tariff Resilience Score Related Terms

FRA:BT3 vs NWBO, ABEO, VRXA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Lineage Cell Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lineage Cell Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's Tariff Resilience Score falls into.


FRA:BT3
78GF Score
Lineage Cell Therapeutics Inc FRA:BT3
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Lineage Cell Therapeutics (FRA:BT3) has a Tariff Resilience Score of 6 as of Jul. 17, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Lineage Cell Therapeutics ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is Lineage Cell Therapeutics' Tariff Resilience Score too high?
Lineage Cell Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Lineage Cell Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, Lineage Cell Therapeutics ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Tariff Resilience Score compare to NWBO and ABEO?
According to the Biotechnology industry distribution chart, Lineage Cell Therapeutics ranks #329 out of 1370 companies for Tariff Resilience Score. This places Lineage Cell Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Lineage Cell Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lineage Cell Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lineage Cell Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Lineage Cell Therapeutics (FRA:BT3) has a current Tariff Resilience Score of 6. The stock's GF Value™ is €1.17, compared to a current price of €1.04 — trading 11.5% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Lineage Cell Therapeutics (FRA:BT3), the current Tariff Resilience Score is 6 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lineage Cell Therapeutics (FRA:BT3) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued. The current stock price of €1.04 is trading 11.5% below its estimated GF Value™ of €1.17.

Key valuation signals for FRA:BT3:

  • Tariff Resilience Score: 6
  • GF Value™: €1.17 vs. price of €1.04 (11.5% below fair value)
  • GF Score™: 78/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#329 of 1370)

No single metric tells the full story. See the FRA:BT3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lineage Cell Therapeutics Business Description

Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score

Get the complete analysis for FRA:BT3

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.04
Price
€1.17
GF Value